Clinical trial assist specialist Medidata has been chosen by CTI Clinical Trial and Consulting, a contract analysis group (CRO) on use of research know-how. The CRO intends to make use of Medidata’s Remote Source Review, to observe operations remotely and evaluate paperwork throughout a number of websites throughout the globe, together with COVID-19 initiatives.
With the pandemic inflicting important interruptions in medical research, websites and sponsors are on the hunt for methods to allow their work to proceed with minimal or no interruption. To that finish, CTI opted to usher in Remote Source Review to assist overcome journey restrictions, sufferers reluctant to go to websites, and different challenges with know-how that helps distant evaluate and different offsite processes.
According to Glen de Vries, co-founder and CEO of Medidata, the corporate is working to advertise methods to develop and deploy know-how enabling websites and sponsors to maintain going.
“We’re pleased to be partnering with CTI on these important, promising trials for patients with rare and infectious diseases, and cancer. It’s more important than ever that we think and plan our way around the obstacles COVID-19 has put in the path of medical progress,” de Vries commented.
According to the corporate, Remote Source Review already is in service at greater than 15,000 medical trial websites. It reportedly proves particularly helpful when essential timelines, affected person safety and information integrity are of specific concern; the instrument additionally helps customers enhance medical analysis affiliate (CRA) productiveness and expense ranges by eliminating time and prices spent on journey.
Timothy Schroeder, CEO and founding father of CTI, mentioned distant options could be particularly helpful when medical trial groups are trying for methods to make sure continuity.
“Standardizing our trials with Medidata technology and enhancing our remote monitoring capabilities are critically important during the pandemic,” he mentioned. “Their scalable solutions will also take us beyond COVID-19. The future lies in minimizing disruptions to research, accelerating the move toward more virtual trial management, ensuring data collection and integrity, and managing source documents remotely, as needed.”